104 related articles for article (PubMed ID: 18288748)
1. Cardiac perforation and tamponade 3 months after transcatheter PFO closure by STARFlex device: A case report.
Motreff P; Dauphin C; Souteyrand G
Catheter Cardiovasc Interv; 2008 Feb; 71(3):412-6. PubMed ID: 18288748
[TBL] [Abstract][Full Text] [Related]
2. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
Spies C; Timmermanns I; Reissmann U; van Essen J; Schräder R
Catheter Cardiovasc Interv; 2008 Feb; 71(3):390-5. PubMed ID: 18288745
[TBL] [Abstract][Full Text] [Related]
3. Implantation of a Occlutech Figulla PFO occluder in a patient with patent foramen ovale and history of embolic stroke.
Krecki R; Peruga JZ; Plewka M; Krzemińska-Pakuła M; Kasprzak JD
Cardiol J; 2008; 15(4):380-2. PubMed ID: 18698549
[TBL] [Abstract][Full Text] [Related]
4. Late cardiac perforation after transcatheter closure of patent foramen ovale mimicking acute type a aortic dissection.
Girdauskas E; Diab M; Secknus MA; Borger MA; Kuntze T
Ann Thorac Surg; 2010 May; 89(5):1649-51. PubMed ID: 20417804
[TBL] [Abstract][Full Text] [Related]
5. Unexpected perforation leading to life-threatening cardiac tamponade six years after patent foramen ovale closure with an intrasept device.
Vandeloo B; Dymarkowski S; Budts W
Acta Cardiol; 2016 Apr; 71(2):247-8. PubMed ID: 27090049
[No Abstract] [Full Text] [Related]
6. Late aortic perforation with an Atriasept device resulting in life-threatening tamponade.
Murphy JC; Walsh SJ; Spence MS
Catheter Cardiovasc Interv; 2010 Jul; 76(1):132-4. PubMed ID: 20578098
[TBL] [Abstract][Full Text] [Related]
7. Two cases of pericardial tamponade due to nitinol wire fracture of a gore septal occluder.
Kumar P; Orford JL; Tobis JM
Catheter Cardiovasc Interv; 2020 Jul; 96(1):219-224. PubMed ID: 31696617
[TBL] [Abstract][Full Text] [Related]
8. Transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Procedural and follow-up results after implantation of the Starflex occluder device with conjunctive intensified anticoagulation regimen.
Fischer D; Fuchs M; Schaefer A; Schieffer B; Jategaonkar S; Hornig B; Drexler H; Meyer GP
J Interv Cardiol; 2008 Apr; 21(2):183-9. PubMed ID: 18312307
[TBL] [Abstract][Full Text] [Related]
9. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occluder.
Silvestry FE; Naseer N; Wiegers SE; Hirshfeld JW; Herrmann HC
Catheter Cardiovasc Interv; 2008 Feb; 71(3):383-7. PubMed ID: 18288733
[TBL] [Abstract][Full Text] [Related]
11. Cardiac perforation during patent foramen ovale closure sealed with an amplatzer PFO occluder.
Chiam PT; Schneider LM; Ruiz CE
J Invasive Cardiol; 2008 Dec; 20(12):665-8. PubMed ID: 19057033
[TBL] [Abstract][Full Text] [Related]
12. Single center experience: Implantation failures, early, and late complications after implantation of a partially biodegradable ASD/PFO-device (BioStar®).
Happel CM; Laser KT; Sigler M; Kececioglu D; Sandica E; Haas NA
Catheter Cardiovasc Interv; 2015 May; 85(6):990-7. PubMed ID: 25511020
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism.
Martín F; Sánchez PL; Doherty E; Colon-Hernandez PJ; Delgado G; Inglessis I; Scott N; Hung J; King ME; Buonanno F; Demirjian Z; de Moor M; Palacios IF
Circulation; 2002 Aug; 106(9):1121-6. PubMed ID: 12196339
[TBL] [Abstract][Full Text] [Related]
14. Role of real-time three-dimensional transoesophageal echocardiography for guiding transcatheter patent foramen ovale closure.
Martin-Reyes R; López-Fernández T; Moreno-Yangüela M; Moreno R; Navas-Lobato MA; Refoyo E; Guzmán G; Domínguez-Melcón F; López-Sendón JL
Eur J Echocardiogr; 2009 Jan; 10(1):148-50. PubMed ID: 18728098
[TBL] [Abstract][Full Text] [Related]
15. Late presentation of CardioSEAL PFO closure device fracture and thrombus formation three years after device implantation.
Narayan V; Puri P; Mehra AO
J Invasive Cardiol; 2008 Aug; 20(8):E247-9. PubMed ID: 18688073
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis, fracture, and percutaneous removal of a patent foramen ovale closure device 1 month after successful deployment.
Gori T; Schräder R; Genth-Zotz S
Catheter Cardiovasc Interv; 2010 Apr; 75(5):778-81. PubMed ID: 20091815
[TBL] [Abstract][Full Text] [Related]
17. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism.
Chatterjee T; Petzsch M; Ince H; Rehders TC; Körber T; Weber F; Schneider H; Auf der Maur C; Nienaber CA
J Interv Cardiol; 2005 Jun; 18(3):173-9. PubMed ID: 15966921
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of patent foramen ovale closure for paradoxical emboli without echocardiographic guidance.
Varma C; Benson LN; Warr MR; Yeo E; Yip J; Jaigobin CS; Webb G; McLaughlin PR
Catheter Cardiovasc Interv; 2004 Aug; 62(4):519-25. PubMed ID: 15274165
[TBL] [Abstract][Full Text] [Related]
19. Challenging closure of a patent foramen ovale via a superior approach.
Bhindi R; Wilson N; Ormerod OJ
J Invasive Cardiol; 2008 Jan; 20(1):E18. PubMed ID: 18174624
[No Abstract] [Full Text] [Related]
20. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale.
Hornung M; Bertog SC; Franke J; Id D; Taaffe M; Wunderlich N; Vaskelyte L; Hofmann I; Sievert H
Eur Heart J; 2013 Nov; 34(43):3362-9. PubMed ID: 23842846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
